Drug Profile


Alternative Names: CS-2164

Latest Information Update: 09 Jun 2017

Price : $50

At a glance

  • Originator Chipscreen Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Aurora kinase B inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 29 May 2017 Chipscreen Biosciences plans a phase I/II trial for Ovarian cancer(Second-line therapy or greater, Refractory metastatic disease) (NCT03166891)
  • 09 May 2017 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (PO) (NCT03074825)
  • 01 Mar 2017 Chipscreen Biosciences plans a phase Ib trial for Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (NCT03074825)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top